Find Clinical Trial

Phase I/II study of S49076, a multi-target inhibitor of c-MET, AXL, FGFR in combination with bevacizumab in patients with recurrent glioblastoma multiforme


← Back
Study Phase Phase 1-2
Therapeutic Area Oncology
Active Substance S049076
SponsorInstitut de Recherches Internationales Servier (I.R.I.S)
Active Substance CodeS049076
Protocol CodeCL1-49076-002
EudraCT Code2013-003079-37
ISRCTN CodeISRCTN11619481


Documents and links

Lay summary READ MORE
Results summary READ MORE




Servier Glossary of Terms

To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.



© 2017 LES LABORATOIRES SERVIER, an incorporated company of Servier.
All Rights Reserved. Servier does not sell its products over the Internet.
More information

Report a side-effect with a drug.